PWS
VRTX icon

Paragon Wealth Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Paragon Wealth Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$534K Hold
1,313
– – 0.15% 21
2023
Q3 		$457K Buy
1,313
+500
+62% +$175K 0.14% 24
2023
Q2 		$286K Hold
813
– – 0.09% 31
2023
Q1 		$256K Buy
813
+150
+23% +$45K 0.16% 32
2022
Q4 		$191K Buy
663
+250
+61% +$76.2K 0.23% 25
2022
Q3 		$120K Buy
+413
New +$119K 0.12% 27

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paragon Wealth Strategies's VRTX Position: Q4 2023 in Review

Paragon Wealth Strategies held its Vertex Pharmaceuticals (VRTX) position steady in Q4 2023 at 1,313 shares worth $534K. The position accounts for 0.15% of the portfolio, ranked #21.

Paragon Wealth Strategies first reported a position in VRTX in Q3 2022 and has held it in 6 quarters since. 1,438 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Paragon Wealth Strategies held 1,313 shares of Vertex Pharmaceuticals worth $534K as of Q4 2023.
  • Paragon Wealth Strategies left its Vertex Pharmaceuticals share count unchanged in Q4 2023.
  • Vertex Pharmaceuticals made up 0.15% of Paragon Wealth Strategies's portfolio in Q4 2023, its #21 holding.
  • Paragon Wealth Strategies first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 6 quarters since.
  • 1,438 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Paragon Wealth Strategies's 13F filing for Q4 2023, filed 3 Jan 2024.